“Sanofi-Aventis [the drug company that makes Acomplia] had long rejected concerns over [Acomplia’s] psychiatric side- effects, but failed to win approval for it from the US Food & Drug Administration,” according to the Financial Times. “Warnings to patients on the drug’s use have been strengthened several times since its launch in Europe in 2006.” “The company said it ‘believes that Acomplia will remain an important therapeutic answer to a highly prevalent and increasing unmet medical need’, and pledged to continue studies on its use for patients with diabetes and at risk of cardiovascular disease.”
© Copyright 2003-2012 - Larry Hobbs - All Rights Reserved.